Vanoxerine dihydrochloride

SKU: orb1300023

Description

Vanoxerine dihydrochloride, also known as GBR-12909 dihydrochloride, is a potent and selective dopamine reuptake inhibitor with an IC50 in the low nanomolar range. This compound is widely used in neuroscience research to study dopaminergic systems, including in vitro binding assays and in vivo models of addiction and Parkinson's disease.

Research Area

Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 67469-78-7
• MW: 523.49
• Purity: 98.35% (May vary between batches)
• Formula: C₂₈H₃₄Cl₂F₂N₂O
• SMILES: Cl.Cl.Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1
• Target: Dopamine Receptor
• Solubility: DMSO:9.4 mg/mL (17.96 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.91 mM)

Bioactivity

• Target IC50:
  Dopamine uptake:1-51 nM
• In Vivo:
  In 9 SP dogs, 11 episodes each of sustained (>10 minutes) AF and AFL were induced. Electrophysiological studies were performed before and after infusion of vanoxerine, which effectively terminated AF and AFL in 19 of 22 episodes. Simultaneous multisite mapping during 3 AF and 3 AFL episodes demonstrated that termination of each arrhythmia occurred with termination of the driver (a reentrant circuit) following an increase in tachycardia CL. Except for conduction in an area of slow conduction in the driver's reentrant circuit, vanoxerine did not significantly affect intraatrial or atrioventricular conduction time, QRS duration, or QT/QTc intervals. Ventricular refractoriness prolonged minimally during ventricular pacing at 400 and 333 ms (176 +/- 16 ms to 182 +/- 16 ms; 173 +/- 11 ms to 178 +/- 18 ms, respectively). Vanoxerine minimally increased (mean 0.7 mA) atrial stimulus threshold for capture.Vanoxerine dihydrochloridealso blocks ligand binding to sigma receptors in rat brain (IC50 = 48 nM).

Storage & Handling

• Storage: keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, I 893 Dihydrochloride, I 893, I893, I-893, I893 Dihydrochloride, I893 dihydrochloride, I-893 Dihydrochloride, GBR12909, GBR 12909, GBR 12909 Dihydrochloride, GBR12909 Dihydrochloride, GBR-12909 dihydrochloride, GBR-12909 Dihydrochloride, GBR-12909, DopamineReceptor, Dopamine Transporter, dopamine uptake, Dopamine Receptor, DAT, SLC6A3, Vanoxerine, Vanoxerine dihydrochloride, Vanoxerine Dihydrochloride

Compound Identifiers

PubChem CID

104920